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Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the principal risk factor associated to end-stage liver diseases
in the world. A study was carried out on end-stage liver disease cases admitted to an important hepatology unit in Medellin, the
second largest city in Colombia. From 131 patients recruited in this prospective study, 71% of cases were diagnosed as cirrhosis,
12.2% as HCC, and 16.8% as cirrhosis and HCC. Regarding the risk factors of these patients, alcohol consumption was the most
frequent (37.4%), followed by viral etiology (17.6%). Blood and/or hepatic tissue samples from patients with serological markers
for HCV or HBV infection were characterized; on the basis of the phylogenetic analysis of HCV 5  UTR and HBV S gene, isolates
belonged to HCV/1 and HBV/F3, respectively. These results conﬁrm the presence of strains associated with poor clinical outcome,
inpatientswithliverdiseaseinColombia;additionally,HBVbasalcorepromoterdoublemutantwasidentiﬁedinHCCcases.Here
we show the ﬁrst study of cirrhosis and/or HCC in Colombian and HBV and HCV molecular characterization of these patients.
Viral aetiology was not the main risk factor in this cohort but alcohol consumption.
1.Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections are a serious health concern due to their global
distribution and direct relationship with liver cirrhosis and
hepatocellular carcinoma (HCC) development. In average,
57 and 78% of cirrhosis and HCC cases are attributable
to these hepatotropic viruses [1, 2]. HCC is the most
common primary liver tumor that presents a heterogeneous
prevalence among diﬀerent ethnic groups and geographic
regions. More than 80% of HCC cases occur in Asia and
Africa: Japan, China, and Niger, holding an incidence of
20–500 cases/100.000 inhabitants; SouthAmericancountries
present a lower incidence (5 cases/100.000 inhabitants),
particularly in Colombia; an incidence of 2 cases/100.000
inhabitants is estimated [3].
Although clinical signiﬁcance of the HBV and HCV
genotypes has not been completely elucidated, increasing
epidemiological data suggests that some genotypes could
be related to higher risk of HCC development [4–8]. For
example, the HCV subtype 1b (HCV/1b) is associated with
more severe clinical outcome and poor antiviral response.
Moreover patients infected with HBV genotype C (HBV/C)
present a higher frequency of HCC than HBV/B-infected
patients [9–13]; patients with HBV/F seem to follow a
similar tendency like HBV/C-infected patients [14, 15]. In
the same way, a double mutation (A1762T/G1764A) in HBV2 Hepatitis Research and Treatment
basal core promoter (BCP) region has been implicated with
severe clinical outcome and poor response to nucleosides’
analogues [4, 16–20].
Considering that Latin American region is extremely
diverse in culture, ethnicity, socioeconomic status, and
health systems, the research ﬁndings of neighbour countries
are not totally comparable. Until now, the epidemiological
pattern of end-stage liver diseases in Colombia is unknown,
and no report has described the molecular characterization
of HBV and HCV in this group of patients [21, 22]. In
the present study, aetiology and viral genotypes, subgeno-
types/subtypes, and HBV pre-C/C mutants were analyzed
in cirrhosis and/or HCC cases attended at the Pablo Tobon
Uribe Hospital (HPTU) during the period 2005–2007 in
Medellin, the second largest city in Colombia.
2.MaterialsandMethods
2.1. Patients. From February 2005 to February 2007, 131
patients with end-stage liver diseases (cirrhosis and/or HCC)
were enrolled in this study; previous voluntary informed
consent sign was obtained. All patients were recruited at
the Hepatology Unit of HPTU in Medellin city, Colombia.
Diagnosis of liver cirrhosis was established according to the
following ﬁndings: hepatic encephalopathy, ascites, digestive
bleeding due to esophageal varices, coagulopathy, sponta-
neous bacterial peritonitis, hepatorenal syndrome, imaging
criteria (ultrasonography, magnetic resonance, and tomog-
raphy), and/or liver biopsy; HCC diagnosis was performed
following the guidelines of the European Association for the
Study of the Liver (EASL).
2.2. Samples. Serum and liver tissue samples were obtained
from patients who underwent liver transplantation. Both
types of material were kept at −70◦C until processing;
the following serological markers were assessed in samples:
HBsAg, total anti-HBc, and anti-HCV (Roche).
2.3. Viral Genome Detection. Total RNA and DNA were
isolated from samples with serological markers for HBV
and/or HCV, using Trizol reagent (Invitrogen, USA). HBV
DNA was ampliﬁed by PCR, using S-gene-speciﬁc primers
[23]. The HCV genome was assessed by nested RT-PCR,
using ﬂanking primers for 5 UTR, following a protocol
previously published [24, 25]. As a positive control, samples
with HBV or HCV genome detection were used; liver tissue
from a patient with diagnosis of cirrhosis associated to
alcohol intake abuse, without HBV or HCV infection, was
used as negative controls. All assays were performed in
duplicate.
2.4. Molecular Characterization of HBV and HCV. In order
to know the viral genotype, diﬀerent PCR products were
sequenced to perform a phylogenetic analysis; HCV geno-
typing was conducted with the 5  conserved region (5 UTR),
using the primers’ set described before for HCV detection
[24, 25]. To amplify the full HBV genome (3200nts), a ﬁrst
round of PCR was performed with P1 and P2 primers [26].
A second round of PCR was carried out with some isolates
using primers 58p-1450n, 1860p-2853n, 2440p-58n, 1101p-
P2, P1-2440n, and 1450p-P2, to obtain the total genome
sequences by subregions’ ampliﬁcation [27]. When total
HBV genome was not ampliﬁed with the primers mentioned
above, the small S gene fragment was ampliﬁed using 58P-
1101N in the ﬁrst round and s3-s3as (319nt) in a second
round [27, 28], or hep3-hep33 as a unique round of PCR
[29].
All sequences obtained were compared with GenBank-
available sequences of known genotypes, including subgeno-
types/subtypes. Phylogenetic analyses by neighbour joining,
maximum parsimony, and maximum likelihood were con-
ducted with PAUP 4.0, MEGA 4.1; Treeview program was
used for tree representation. Recombination events were
studied by bootscanning and similarity analysis (Simplot).
To evaluate mutations in HBV BCP (A1762T/G1764A)
and pre-C/C (G1896A), analysis of the sequences was
carried out by comparison with other GenBank sequences
of diﬀerent HBV genotypes considering mutants and wild
type. BioEdit program was used for this purpose. The
accession numbers of sequences included are as follows:
HBV: FJ589065; FJ589066; FJ589067; FJ589068; FJ589069;
FJ589070; HCV: JF693486, JF693487, JF693488, JF693489.
3. Results
3.1.DemographicandClinicalCharacteristicsofPatients. The
mean age of the 131 individuals was 58.1 years (range: 17–
85 years); most of patients recruited were males (65.6%).
According to the followed clinical guidelines, 71% evidenced
cirrhosis, 12.2% HCC, and 16.8% cirrhosis and HCC
(HCC/Ci∗). Interestingly, when risk factors were analyzed
alcohol intake abuse was the most frequent risk factor
(37.4%), followed by viral etiology (17.6%), autoimmunity
(9.9), NASH (7.6%), and other causes such as metabolic
disorders and biliary disease (16.8%); 10.7% of the cases
were not associated to any risk factor assessed (Table 1). The
mostfrequentclinicalmanifestationswereesophagealvarices
(64%), ascites (61.8%), coagulopathy (46%), and hepatic
encephalopathy (38.2%); most of patients were scored at the
Child B and C (>75%), indicating an advanced chronic liver
disease in patients enrolled.
From 131 patients included in the present study, 14 were
positive for the HBsAg serological marker (10.7%) and 9
for anti-HCV (6.9%); most of patients infected by HBV and
HCV were males (60.8%). The mean age of these 23 patients
was 56.6 (range 34–74 years). Among them, 22 had diagnosis
of liver cirrhosis and 7 had HCC in addition (HCC/Ci∗);
just one patient had diagnosis of HCC without cirrhosis.
According to the phenotype, 20 patients corresponded to
non-Amerindian individuals; besides, the three others were
patients from El Salvador, Venezuela, and Israel (Table 2).
3.2. Phylogenetic Analysis. In 4 out of 8 tissue samples from
patients infected by HCV, it was possible to successfully
sequence the 5 UTR. The expected grouping was observed
among Genbank sequences after phylogenetic analysisHepatitis Research and Treatment 3
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Figure 1: Unrooted Tree generated with MEGA software, using 5’UTR HCV sequences. Solid green circle indicates the position of isolate
characterized in the present study. The accession number of the sequences are shown.
conduction, with minor method-dependent changes (data
not shown). All four isolates belonged to HCV genotype 1.
Three HCV strains corresponded to HCV subtype 1b and
one to subtype 1a (Figure 1).
In the case of HBV, seven strains were sequenced; four
strains from liver tissues and three were serum sample
derived. In one additional isolate (UdeA-072) the HBV
genome was detected by PCR, although it was not possible
to obtain a clear electropherogram after several assays. HBV
S gene sequence analysis showed that all isolates belonged to
genotype HBV/F, validated by the HBV GenBank sequence
grouping results and high bootstrap values observed in
most tree branches. Similar topology was observed among
trees generated by the diﬀerent inference methods (data4 Hepatitis Research and Treatment
Table 1: Description of End-stage liver disease cases recruited.
Characteristics Proportion (%)
Risk factors
Alcohol intake 37,4
Viral etiology 17,6
Cryptogenic 10,7
Autoimmunity 9,9
NASH 7,6
Others∗ 16,8
Clinical ﬁndings
Esophageal varices 64
Ascites 61,8
Coagulopathy 46
Hepatic encephalopathy 38,2
Spontaneous bacterial peritonitis 15,7
Hepatorenal syndrome 8,9
∗Metabolic disorders, biliary disease, or both.
not shown). Five isolates grouped into the clade of South
American strains (Codes UdeA-009, UdeA-054, UdeA-056,
UdeA-083, and UdeA-089); this clade included the ﬁrst
Colombian isolate characterized by Norder et al. [29].
Interestingly, one of the sequences analyzed (Code UdeA-
024) was less related to this clade (Figure 2).
The complete HBV genome was sequenced in four
strains,twoColombianisolates(CodesUdeA-083andUdeA-
089) one from Venezuela (Code UdeA-054), corresponding
to subgenotype F3 (HBV/F3), and the sequence from El
Salvador (Code UdeA-024), grouped in a diﬀerent clade
from the HBV/F3 (Figure 3). Indeed, UdeA-024, belonging
to subgenotype F1a (HBV/F1a), was more closely related to
strains from Central America countries (El Salvador, Costa
Rica, and Nicaragua), in agreement with the origin of the
patient. In the same phylogenetic analysis, partial sequences
(S gen) of strains UdeA-009 and UdeA-056 were added. On
the basis of strict consensus tree generated by maximum
parsimony, these isolates corresponded to HBV/F3; this
grouping was supported by a bootstrap value higher than 80.
The results obtained in the present phylogenetic anal-
ysis are in agreement with the HBV and HCV genotype
geographic distribution in Latin America. Additionally, this
report corresponds to the ﬁrst description of HBV/F in
Colombian patients with severe liver disease.
3.3. Characterization of G1896A and A1762T/G1764A
Mutants. To establish the presence of G1896A and
A1762T/G1764A mutants, pre-C/C sequences were aligned
with HBV wild-type and mutant prototypes available
in GenBank. The BCP analysis showed that isolates
UdeA-083 and UdeA-089 carried the double mutation
A1762T/G1764A. These isolates were recovered from the
Colombian patients with diagnosis of HCC/Ci∗ (Table 3).
In addition, T at 1858 nucleotide (T1858)w a sd e t e c t e d
in isolates UdeA-024 and UdeA-054 and C1858 in samples
UdeA-083andUdeA-089.InUdeA-054,mutantG1896Awas
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Figure 2: Phylogenetic tree of HBV genotype A to H generated
by the Neighbour Joining method (PAUP), using HBV S gene
sequences The Hepatitis Woolly monkey virus (WM) sequence was
used as outgroup. Red arrow: isolate characterized from cirrhosis
and/or HCC cases. The accession number followed by genotype
identity is indicated. Bootstrap values are shown (1000 repetitions).
HKY was used to assess distances.
also identiﬁed in addition to T1858. The G1896A mutation
correlated with detection of no HBeAg by ELISA in the
corresponding serum sample (Table 3).
4. Discussion
Thispapercorrespondstotheﬁrststudyofaetiologydescrip-
tion in Colombian patients with end-stage liver diseases and
the molecular characterization of HBV and HCV strains
detected in this group of patients.
One of forty deaths around the world is due to end-
stage liver disease. In the present study, 71% of the patients
correspond to cirrhosis cases and 29% to HCC, a similar
result to other descriptions reported in countries of the
region [1, 30, 31]. Among these 131 patients, alcohol
intake abuse was the most frequent risk factor observed
(37.4%), followed by viral infections (17.6%). AlthoughHepatitis Research and Treatment 5
Table 2: Clinical and demographic characteristics of patients with positive serological markers for HBV and HCV.
Code Diagnosis Origin Age Gender Alcohol∗ Type of simple Serological marker
Serum Liver
tissue HBsAg Anti-HCV
UdeA-001 Ci Colombia 68 F 4 NA Yes Neg Pos
UdeA-002 Ci Colombia 59 M 4 NA Yes Neg Pos
UdeA-003 Ci Colombia 68 M 4 NA Yes Neg Pos
UdeA-004 Ci Colombia 47 M 4 Yes NA Pos Neg
UdeA-006 HCC + Ci Colombia 48 M 4 NA Yes Neg Pos
UdeA-009 Ci Colombia 69 M 1 Yes NA Pos Neg
UdeA-015 HCC + Ci Colombia 68 F 9 NA Yes Neg Pos
UdeA-024 Ci El Salvador 60 M 9 NA Yes Pos Neg
UdeA-054 Ci Venezuela 47 M 3 Yes Yes Pos Neg
UdeA-056 HCC + Ci Colombia 56 F 4 Yes NA Pos Neg
UdeA-058 HCC + Ci Colombia 53 M 9 Yes NA Pos Neg
UdeA-061 Ci Colombia 47 F 4 Yes NA Pos Neg
UdeA-065 Ci Colombia 58 F 1 NA Yes Neg Pos
UdeA-069 HCC Colombia 64 F 4 NA Yes Neg Pos
UdeA-070 Ci Colombia 34 M 4 NA Yes Neg Pos
UdeA-072 Ci Israel 49 M 3 Yes Yes Pos Neg
UdeA-077 Ci Colombia 57 M 1 Yes NA Pos Neg
UdeA-083 HCC + Ci Colombia 67 F 4 Yes Yes Pos Neg
UdeA-087 Ci Colombia 48 M 2 Yes NA Pos Neg
UdeA-089 HCC + Ci Colombia 47 F 4 Yes Yes Pos Neg
UdeA-099 Ci Colombia 56 M 4 Yes NA Pos Neg
UdeA-101 Ci Colombia 74 F 4 Yes NA Pos Neg
UdeA-124 HCC + Ci Colombia 57 M 2 Yes NA Pos Neg
ci: Cirrhosis, HCC: hepatocellular carcinoma, M: male, F: female, ∗Alcohol intake: for male/(female) 1: >80g/day (40g/day); 2: 50–80g/day (20–40g/day); 3:
<50g/day (20g/day) 4: no intake; 9: no data; Yes: available; NA: nonavailable; Yes: HBV/HCV-positive sample by molecular analysis; Pos: positive serological
result;Neg: negative serological result.
Table 3:MolecularcharacterizationofHBVisolatescorrespondingtoEnd-stageliverdiseasecases:Genotype,Subgenotypeandprecore/core
mutants.
Code Diagnosis Genotype Subgenotype
Mutation HBV serological markers
pre-C BCP HBsAg IgG
anti-HBc HBeAg
1858 1896 1762 1764
UdeA-009 Ci F F3μ ———— P o s P o s N e g
UdeA-024 Ci F F1a∞ TGAG P o s P o s N e g
UdeA-054 Ci F F3∞ TA α AG P o s P o s N e g
UdeA-056 HCC/Ci∗ FF 3 μ ———— P o s P o s N e g
UdeA-083 HCC/Ci∗ FF 3 ∞ CG T ∗ A∗ Pos Pos Neg
UdeA-089β HCC/Ci∗ FF 3 ∞ CG T ∗ A∗ Pos Pos Neg
β:b o t h ,t i s s u ea n ds e r u ms a m p l e s ,C i :c i r r h o s i s ,H C C / C i ∗: cirrhosis and hepatocellular carcinoma, ∞: based on complete genome analysis, μ: based on S gene
sequence analysis, —: no data, α: nonsense mutation, ∗: double mutant, Pos: positive, Neg: negative. Strains isolated from Colombian patients: UdeA-009,
UdeA-024, UdeA-056, UdeA-083, and UdeA-089. Strain isolated from a Venezuelan patient: UdeA-54. 1.
this epidemiological pattern is usually found in developed
countries, the high proportion of males (in general males
have a higher alcohol intake than females) in the present
study and the HBV vaccination status in Colombia could
be contributing to the risk factors’ pattern of the population
study [32]. On the other hand, the prevalence of cryptogenic
cirrhosis and autoimmune liver disease is according to
previous reports [1, 30].
As previously mentioned, the frequency of cirrhosis and
HCC cases associated to viral etiology in the present study6 Hepatitis Research and Treatment
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Figure 3: HBV subgenotyping (F1-F4), based on the complete
genome analysis using PAUP program. Sequence of genotype G
was used as outgroup (AB056513). The accession number and
subgenotype are indicated followed by the isolate origin letters
code (Sal: El Salvador, CR: Costa Rica, Nic: Nicaragua, Jap: Japan,
Arg: Argentina, Ven: Venezuela, Col: Colombia, Pan: Panama, Bol:
Bolivia, and two Amerindian tribes from Venezuela War: Warao
tribe, Japre: Japreira tribe). Red arrow: sequences belonging to the
present study. Bootstrap values are shown (1000 replications).
was low (17.6%; 23/131). Only 10.7% (14/131) and 6.9%
(9/131)ofthesepatientswerepositiveforserologicalmarkers
ofHBV(HBsAg)orHCV(anti-HCV) infection,respectively.
TheHCV-relatedHCChasincreasedinseveralcountries;
80% of infected patients with HCV progress to chronic
infection, while 20% of them develop cirrhosis, and at least
5% of these evolve to HCC [33]. In Latin America, the
world health organization (WHO) estimates an intermediate
prevalence of HCV infection (1–2.5%); moreover, a low
prevalence (0.5–1%) has been reported among Colombian
blood donor population [34–36].
As previously mentioned, Medellin is the second largest
city in the country and the capital of Antioquia State
(Department of Antioquia). Health authorities in Antioquia
have reported a similar HCV prevalence since 2004 (0.2–
0.3/100.000 inhabitants) (Indicadores B´ asicos 2004–2007).
Contrary to general population, studies in some Latin
American countries show a high HCV prevalence in severe
liverdisease.Indeed,HCVinfectionisthepredominantHCC
risk factor in Argentina, Chile, and southeastern states of
Brazil. Furthermore, in a recently prospective multicenter
study of HCC cases from 9 Latin American countries,
the main HCC risk factor was HCV infection (30.8%),
followed by alcohol (20.4%), HBV infection (10.8%), and
then HCV plus alcohol (5.8%) [37–39]. A similar tendency
was observed in Mexican cirrhotic patients, where 39.5% of
recruited patients presented alcohol intake abuse, followed
by HCV infection (36.6%) [40].
Considering the analysis of HCV sequences included in
the phylogenetic analysis, the prototypes clustered according
to the genotypes described in the literature (HCV/1-6),
obtaining similar results with all methods conducted. Inside
the main cluster of genotype HCV/1 was clearly observed
cladesassignedtosubtypeHCV/1aandHCV/1b;Colombian
strains were grouping into these subtypes. Indeed, one
isolate belongs to HCV/1a and three strains to HCV/1b.
This result is consistent with previous reports of HCV
geographic distribution in Latin American countries where
diﬀerentgenotypesarepresent(HCV/1,HCV/2,HCV/3,and
HCV/4); however, genotype HCV/1 is the prevalent in most
countries of the region including Colombia [41]. Indeed,
HCV/1 has been described in some studies performed by
diﬀerent approaches in Colombian multitransfused patients,
individuals with elevated aminotransferases, general popula-
tion, and kidney transplant patients [42–45]. This is the ﬁrst
report based on sequence analysis and developed in samples
of patients with severe liver disease in Colombia. Secondly,
most of research ﬁndings agree that HCV/1b is related with
higher risk of severe liver disease [23, 46–48]. It is important
for health authorities in Colombia and other Latin American
countries to develop studies that contribute to knowing the
impact of genotype HCV/1b over the hepatitis C natural
history in the region.
According to WHO, Colombia has a moderate endemic-
ity for hepatitis B, although there are several epidemio-
logical patterns given the geographic, ethnic, cultural, and
socioeconomic status of the population. Actually, Sierra
Nevada de Santa Marta, Orinoquian and Amazon basins,
and southeastern part of the country corresponded to high-
prevalence regions for hepatitis B infection in this country.
However Antioquia state holds a diﬀerent behavior [49]; in
fact, the general incidence of HBV infection in this state
in the last years range was 2.7–4.4 per 100.000 inhabitants,
while the prevalence in blood donors was 0.3% [49, 50]. As
mentioned above, HBV infection was observed in 10.7% of
the patients analyzed. The study population was recruited
in Medellin, the second largest city in Colombia, in one
of the most important units of hepatology in the country;
even if it is possible that this hospital receives patients from
rural area of Antioquia state and other Colombian states,
most of the cases corresponded to people living in urban
area and not from high-prevalence regions of hepatitis B
infection.Hepatitis Research and Treatment 7
This heterogeneity of hepatitis B situation is also
described in Brazil; indeed, higher frequency of HBV
infection than other risk factors has been described in HCC
patients from states of northeastern and northern regions of
Brazil but not in patients from southeastern states [51, 52].
The low HBV prevalence described in the present study
contrasts with some studies conducted in Peru and Brazil,
where HBV was reported in 42–63% of end-stage liver
disease cases [51–56]. Contrary to these reports, a low HBV
prevalence has been described among HCC patients from
Chile (6.8%) and Puerto Rico (4%) [57, 58], similar to
other works carried out in the United States, Japan, and
western Europe [1]. On the other hand, on Ecuador a study
conducted in 770 cirrhotic patients linked viral etiology to
2.8% of the cases, while alcohol intake was the most frequent
risk factor associated (48.3%) [59]. Whereas diﬀerences
among studied populations (gender, age, origin), diagnosis,
and viral markers are described above, additional studies will
be necessary for clarifying the real statement of hepatotropic
viruses in cases of cirrhosis and HCC/Ci∗ in Colombia and
the region.
On the other hand, the phylogenetic analysis of HBV
showed that HBV/F and subgenotype HBV/F3 were pre-
sented in serum and tissue samples of the Colombian
population analyzed; subgenotypes HBV/F1a and HBV/F3
were also detected in two cases from El Salvador and
Venezuela, respectively. These results are consistent with
previously published reports about molecular diversity of
these hepatotropic viruses, geographic distribution in Latin
America, and their prevalence in severe forms of hepatic
disease. In addition, the A1762T/G1764A double mutant,
associated according to some authors with a poor clinical
outcome, was described in strains isolated from Colombian
patients with diagnosis of HCC/Ci∗.A sm e n t i o n e db e f o r e
all isolates of HBV sequenced belonged to HBV/F. It has
been proposed that HBV/F is autochthonous to America
due to its predominance in diﬀerent ethnic groups, in
particular Amerindian [60]. In Colombia, few studies about
HBV molecular characterization have been published. Two
of them included samples from blood donor populations,
showing a predominance of genotype HBV/F (77–87.23%)
[21, 22]. This result is in agreement with our study and
previous ﬁndings of genetic population founder carried out
in the state of Antioquia [61, 62], which revealed that 90%
of the genetic pool (mitochondrial DNA) corresponded to
Amerindian origin. More recently, in Colombia was detected
the genotype HBV/E in nine pregnant women, being the ﬁrst
description of an exclusively African HBV genotype circulat-
inginSouthAmerica[63];thisresultalsocoincideswithhigh
frequency of African haplotypes in population from Choco
state, at the paciﬁc coast of Colombia [64]. The subgeno-
types HBV/F1-F4 have a speciﬁc geographic distribution
in America. Indeed, subgenotype HBV/F1a is predominant
in Alaska, Nicaragua, Costa Rica, and El Salvador, while
subgenotype HBV/F1b in Peru and Argentina. Subgenotype
HBV/F2 is prevalent in Venezuela and Brazil and subgeno-
type HBV/F3 in Panama, Venezuela, and Colombia. Finally,
subgenotype HBV/F4 is present in Bolivia and Argentina
[20, 65]. Devesa et al. and Alvarado et al. have characterized
the HBV subgenotypes in samples from Colombian blood
donor isolates; most of the isolates corresponded to HBV/F3.
Genotype HBV/F was also recently characterized in samples
from blood donor population from Medellin by our group
(unpublished data). In the present study, the complete
genomeanalysisin4outof6HBVisolatesfrompatientswith
cirrhosis or HCC/Ci∗ made it possible to classify 3 of them
into subgenotype HBV/F3, and one strain into subgenotype
HBV/F1a, while partial analysis (small S gene sequence) of
two others showed grouping with HBV/F3 prototypes.
The BCP and pre-C/C mutations have been associated
with clinical outcome severity. One frequent mutation cor-
responds to G1896A in the pre-C/C region which leads to a
premature stop codon preventing HBeAg synthesis [4, 8, 20,
66]. When this region was analyzed, the G1896A mutation
was characterized only in one isolate (UdeA-054), presenting
in addition T1858, while the isolates UdeA-083 and UdeA-089
carry C1858. According to several studies, G1896A is frequent
in genotype HBV/F isolates that carry T1858. A hypothesis for
this coevolution pattern is that hydrogen binding between
nucleotides 1858–1896 is necessary to maintain the low stem
secondary structure of ε signal [67]. The presence of G1896A
in isolate UdeA-054 correlated with no detection of HBeAg
by ELISA in serum sample (Table 3).
When BCP was analyzed, it was demonstrated that
isolates UdeA-083 and UdeA-089 carried the double muta-
tion A1762T/G1764A; these isolates corresponded to two
Colombian patients with diagnosis of HCC/Ci∗.
Regarding the prevalence of double mutation in BCP in
isolates of genotype HBV/F, there are diﬀerent results. In
fact, in Brazilian patients with chronic infection, the BCP
double mutation was described in 90% of HBV/F isolates;
this double mutation was not identiﬁed in any other samples
of these studies [68, 69].
Several authors have proposed that HBV genotype and
BCP mutants could be related with liver disease severity.
Although HBV/B and HBV/C circulate in Asia, patients with
diagnosis of HBV-related HCC present a higher prevalence
of HBV/C infection [9, 12, 13]. Similar ﬁndings have been
reported for HBV/F, in a prospective study of 258 patients
with chronic HBV infection; after a mean followup of 94
months, the mortality rate related to liver disease was more
frequent in cases of genotype HBV/F than HBV/ A and
HBV/D infection [14]. Livingston et al. also described an
association of HBV/F and liver disease severity, in particular
HCC risk. They compared the frequency of HBV/F in Alaska
natives with chronic hepatitis B infection with or without
HCC; the frequency of genotype HBV/F was 68% and
18%, respectively [15]. This ﬁnding suggested a higher risk
of HCC development in HBV/F cases [15, 60]. Sanchez-
Tapias et al. and Livingston et al. described that genotype
HBV/F, autochthonous to America, could be related with
poor clinical outcome and higher HCC risk development;
however, a higher number of studies should be developed for
a stronger support of these ﬁndings.
In addition, the present study is the ﬁrst report of
A1762T/G1764A in Colombian HBV isolates. Recent studies
assign a more important role to A1762T/G1764A in hepa-
tocarcinogenesis than the HBV genotype itself. It has been8 Hepatitis Research and Treatment
demonstratedthat the BCP double mutation generatesa new
binding site for the transcription factor HNF1, regulating
pgRNA transcription and promoting an enhancement of
HBV replicative activity [70]. In patients with HCC due to
HBV infection, isolates belonging to genotype HBV/C carry
a higher frequency of A1762T/G1764A compared to HBV/B
strains[4,9,71,72].Inourstudy,thepresenceofBCPdouble
mutation correlates with HCC diagnosis in those patients.
This study corresponds to the ﬁrst description of end-
stage liver diseases and the molecular characterization of
HBV and HCV in cirrhosis and HCC/Ci∗ cases in Colombia.
Genotype HCV/1 and genotype HBV/F (subgenotype F3)
were detected in samples belonging to Colombian patients.
This result agrees with previous studies and in the case
of HBV with genetic founder populations in Colombia.
Additionally, HBV/F3 and HBV/F1a were characterized in
isolates from patients from Venezuela and El Salvador,
respectively. The HBV and HCV subgenotyping/subtyping
results obtained in the present study are according to the
geographic pattern and predominance described for these
hepatotropic viruses, especially subgenotypes HBV/F1a and
HBV/F3 in Central and South America, respectively.
On the other hand, mutation of A1762T/G1764A was
characterized in isolates from patients with HCC. Although
the double mutant has been related with higher risk of
HCC development, the descriptive design of our study and
limited sample size do not allow us to assess any type of
statistical association between BCP mutant, genotype, and
clinical outcome. Additionally studies will be necessary to
determine whether HCV/1b, HBV/F, and pre-C/C variants
are associated with a higher risk of cirrhosis and HCC
development.
Moreover, the statement of viral etiology and alcohol
intake abuse in end-stage liver disease cases in Colombia and
Latin America should be explored in further case-control
studies.
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